Botulinum toxin type A injections can be an effective treatment for pain in children with hip spasms and cerebral palsy

Developmental Medicine and Child Neurology

Volumn 51, Issue 9, 2009, Pages 705-710

  Lundy, Claire T ^a   Doherty, Gary M ^b   Fairhurst, Charlie B ^a  

^a EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADOLESCENT; ADULT; ARTICLE; BODY EQUILIBRIUM; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; DAILY LIFE ACTIVITY; DRUG EFFICACY; DYSTONIA; FEMALE; FUNCTIONAL DISEASE; GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM LEVEL 5; HAMSTRING; HIP DISLOCATION; HIP PAIN; HUMAN; ILIOPSOAS MUSCLE; MALE; MUSCLE SPASM; MUSCLE TONE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUADRIPLEGIA; QUALITY OF LIFE; RATING SCALE; SLEEP PATTERN; SPASTICITY; SUBLUXATION;

ADOLESCENT; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HIP; HUMANS; MALE; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; PAIN; PAIN MEASUREMENT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68549087251     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2009.03315.x     Document Type: Article

References (27)

1. Cans C. Surveillance of cerebral palsy in Europe: A collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol 2000; 42: 816-24.
2. Cooke PH, Cole WG, Carey RP. Dislocation of the hip in cerebral palsy. Natural history and predictability. J Bone Joint Surg Br 1989; 71: 441-46.
3. Cooperman DR, Bartucci E, Dietrick E, Millar EA. Hip dislocation in spastic cerebral palsy: Long-term consequences. J Pediatr Orthop 1987; 7: 268-76.
4. Gamble JG, Rinsky LA, Bleck EE. Established hip dislocations in children with cerebral palsy. Clin Orthop Relat Res 1990; 253: 90-99.
5. Pountney T, Green EM. Hip dislocation in cerebral palsy. BMJ 2006; 332: 772-75.
6. Samilson RL, Tsou P, Aamoth G, Green WM. Dislocation and subluxation of the hip in cerebral palsy. Pathogenesis, natural history and management. J Bone Joint Surg 1972; 54: 863-73.
7. Scrutton D, Baird G. Surveillance measures of the hips of children with bilateral cerebral palsy. Arch Dis Child 1997; 76: 381-84.
8. Dobson F, Boyd RN, Parrott J, Nattrass GR, Graham HK. Hip surveillance in children with cerebral palsy. Impact on the surgical management of spastic hip disease. J Bone Joint Surg Br 2002; 84: 720-26.
9. Barwood S, Baillieu C, Boyd R et al. Analgesic effects of botulinum toxin A: A randomized, placebo-controlled clinical trial. Dev Med Child Neurol 2000; 42: 116-21.
10. McKearnan KA, Kieckhefer GM, Engel JM, Jensen MP, Labyak S. Pain in children with cerebral palsy: A review. J Neurosci Nurs 2004; 36: 252-59.
11. Roscigno CI. Addressing spasticity-related pain in children with spastic cerebral palsy. J Neurosci Nurs 2002; 34: 123-33.
12. Hagglund G, Andersson S, Duppe H, Lauge-Pedersen H, Nordmark E, Westbom L. Prevention of severe contractures might replace multilevel surgery in cerebral palsy: Results of a population-based health care programme and new techniques to reduce spasticity. J Pediatr Orthop B 2005; 14: 269-73.
13. Verrotti A, Greco R, Spalice A, Chiarelli F, Iannetti P. Pharmacotherapy of spasticity in children with cerebral palsy. Pediatr Neurol 2006; 34: 1-6.
14. Berweck S, Heinen F. Use of botulinum toxin in pediatric spasticity (cerebral palsy). Mov Disord 2004; 19(Suppl. 8): S162-7.
15. Berweck S, Schroeder AS, Fietzek UM, Heinen F. Sonography-guided injection of botulinum toxin in children with cerebral palsy. Lancet 2004; 1363: 249-50.
16. Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994; 36: 386-96.
17. Eames NW, Baker R, Hill N, Graham K, Taylor T, Cosgrove A. The effect of botulinum toxin A on gastrocnemius length: Magnitude and duration of response. Dev Med Child Neurol 1999; 41: 226-32.
18. Graham HK, Aoki KR, Autti-Rämö I, et.al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000; 11: 67-79.
19. Heinen F, Molenaers G, Fairhurst C, et al. European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2006; 10: 215-25.
20. Wissel J, Muller J, Dressnandt J et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000; 20: 44-49.
21. Breau LM, Finley GA, McGrath PJ, Camfield CS. Validation of the non-communicating children's pain checklist - postoperative version. Anesthesiology 2002; 96: 528-35.
22. Houlihan CM, O'Donnell M, Conaway M, Stevenson RD. Bodily pain and health-related quality of life in children with cerebral palsy. Dev Med Child Neurol 2004; 46: 305-10.
23. Hunt A, Goldman A, Seers K, et al. Clinical validation of the paediatric pain profile. Dev Med Child Neurol 2004; 46: 9-18.
24. Oberlander TF, O'Donnell ME. Beliefs about pain among professionals working with children with significant neurologic impairment. Dev Med Child Neurol 2001; 43: 138-40.
25. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003; 43(Suppl. 1): S9-15.
26. Naumann M, So Y, Argoff CE, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1707-14.
27. Voller B, Sycha T, Gustorff B, et al. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 2003; 14: 940-44.